Nob Hill Therapeutics

Nob Hill Therapeutics, Inc. (NHT) is an early-stage biopharmaceutical company, established in 2016 and based in Albuquerque, New Mexico. The company was founded by VIC Technology Venture Development to commercialize a novel drug delivery platform. NHT is focused on addressing severe respiratory diseases, including lower respiratory tract infections, which are a leading cause of death globally. The company's operations are financially supported through a combination of grant funding and venture capital, having raised a total of $3.67M over 11 rounds, including a significant $3M Series A in August 2024 led by Tramway Venture Partners.

The core of Nob Hill's business is its proprietary DryNeb™ technology, a first-of-its-kind dry powder nebulizer. This patented platform is designed to overcome the limitations of traditional dry powder inhalers (DPIs), which often require forceful inhalation—a challenge for patients with compromised lung function. The DryNeb™ disperses drug powder independently of the patient's breath by using a magnetically responsive element, ensuring a reproducible and high-efficiency delivery of medication directly to the lower respiratory tract. This allows for the administration of high doses of pure active ingredients without requiring liquid formulations or coordination from the patient, making it suitable for a wide range of individuals, including those with significantly impaired inhalation capabilities.

The company's business model involves a dual strategy. Firstly, it aims to partner with or license its DryNeb™ platform to large pharmaceutical companies looking for more effective drug delivery systems. Secondly, NHT is developing its own pipeline of therapeutics, initially focusing on repurposing existing FDA-approved drugs for orphan indications to streamline the path to market. Their lead product candidates include an antifungal for Allergic Bronchopulmonary Aspergillosis (ABPA) in cystic fibrosis patients and antibiotic treatments for nontuberculous mycobacterial (NTM) infections. The company has secured multiple Small Business Innovation Research (SBIR) grants to advance these therapies through preclinical development and towards Investigational New Drug (IND) applications with the FDA. Under the leadership of CEO Noel Greenberger, who joined in September 2022, Nob Hill is advancing its technology and therapeutics, including therapies for lung cancer, through pre-IND studies.

Keywords: Nob Hill Therapeutics, DryNeb, dry powder nebulizer, inhalation drug delivery, respiratory diseases, lower respiratory tract infections, pulmonary medicine, orphan drug development, VIC Technology Venture Development, Noel Greenberger, Tramway Venture Partners, cystic fibrosis treatment, lung infection therapy, high-dose lung delivery, preclinical studies, biopharmaceutical, medtech, Albuquerque startup, inhalation toxicology, SBIR grant recipient, antifungal inhaler, antibiotic inhaler, respiratory drug delivery platform